Can-Fite Launches Phase 2 Piclidenoson Trial for Lowe Syndrome
RAMAT GAN, Israel, Aug. 3, 2026 Can-Fite BioPharma Ltd. has launched its first clinical development program evaluating Piclidenoson for...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
RAMAT GAN, Israel, Aug. 3, 2026 Can-Fite BioPharma Ltd. has launched its first clinical development program evaluating Piclidenoson for...
RESEARCH TRIANGLE PARK, N.C., Aug. 3, 2026 Opus Genetics, Inc. has completed patient enrollment in its registrational Phase 3...
BERKELEY HEIGHTS, N.J., Aug. 3, 2026 Tonix Pharmaceuticals Holding Corp. announced that it has received official Type C meeting...
